TALIPEXOLE DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N3S.2ClH
Molecular Weight	282.233
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DPQAXNSOFFYKDS-UHFFFAOYSA-N

InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H

HIDE SMILES / InChI

Description
Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	5.8 null [pKi]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	7.0 null [pKi]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.43 null [pKi]
Alpha-2b adrenergic receptor 27 Target ID: CHEMBL1942 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.09 null [pKi]
Alpha-2c adrenergic receptor 37 Target ID: CHEMBL1916 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.37 null [pKi]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	6.48 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic schizophrenia 6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8102551	Primary		Preclinical	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.	2001 Apr 6	11301060
Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.	2001 Aug	11498509
[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].	2001 May	11428377
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.	2001 May	11383713
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.	2001 May 1	11301041
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.	2001 Nov-Dec	11777250
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.	2001 Oct	11606316
Influence of sildenafil on central dopamine-mediated behaviour in male rats.	2002 Feb 15	11895101
Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models.	2002 Jan	11853125
Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat.	2002 Mar	12047035
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.	2002 Nov	12388666
Effects of an alpha2-adrenoceptor agonist in nasal mucosa.	2003 Oct	15764068
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.	2004 Apr 5	15063161
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.	2006	16569938
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.	2007	17266136
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.	2007 Sep	18404453
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?	2008 Mar	17680806
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.	2009 Feb	19146631
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury.	2009 Jan-Mar	20046643

Patents

Sample Use Guides

In Vivo Use Guide

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells

Name

Type

Language

TALIPEXOLE DIHYDROCHLORIDE

Common Name

English

TALIPEXOLE HYDROCHLORIDE

Common Name

English

TALIPEXOLE DIHYDROCHLORIDE [MI]

Common Name

English

Talipexole hydrochloride [WHO-DD]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [JAN]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [MART.]

Common Name

English

TALIPEXOLE HCL

Common Name

English

Code System Code Type Description

CAS

36085-73-1